31 results about "Respiratory allergy" patented technology

This invention pertains to inhibitors of atrial natriuretic peptide receptor A (NPRA) function, such as small interfering RNA (siRNA), useful for reducing the inflammation associated with many human diseases, such as asthma, respiratory syncytial virus (RSV) infection, and cancers (such as melanoma, lung cancer, and / or ovarian cancer) by interfering with NPRA gene expression or otherwise reducing NPRA function within a subject; and methods for treating a subject suffering from, or at risk of developing, an inflammatory disease, respiratory allergy (such as allergic rhinitis and asthma), viral infection, and / or cancer by administering such NPRA inhibitors to the subject.

The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children. The invention also relates to compositions for use in such methods, as well as their manufacture. The invention may be used to cause protection against any allergy, particularly food or respiratory allergies.

The invention provides compounds of Formula (I), stereoisomers thereof, or pharmaceutically acceptable salts of said compounds or stereoisomers, wherein R1, R2, m, p, q, R7 and R8 are as defined below, as well as compositions comprising the same, processes for making the same, and methods of using the same to treat a variety of diseases, including, those requiring interaction with metalloproteases, and more specifically with macrophage metalloelastase (MMP-12), and for the prevention and treatment of respiratory pathologies such as chronic obstructive bronchopneumopathy (COPD), emphysema, chronic bronchitis, chronic pulmonary inflammation, asthma, cystic fibrosis, acute respiratory distress syndrome (ARDS), respiratory allergies including allergic rhinitis, and also diseases associated with the production of TNFα including severe fibrotic pulmonary disease, pulmonary sarcoidosis and silicosis. The compounds of the present invention also show inhibitory activity on metalloprotease-13 (MMP-13), making them useful for the treatment of pathologies involving this enzyme, such as cancer, osteoporosis, osteoarthritis, arthritis, rheumatoid arthritis, atherosclerosis, multiple sclerosis and cardiac insufficiency.

Pharmaceutical compositions consisting of diphenhydramine tannate in solid dosage form which are effective when administered for the symptomatic relief of sneezing, itchy, watery eyes, itchy nose or throat and runny nose due to hay fever (allergic rhinitis) or other respiratory allergies are disclosed.

The invention provides compounds of Formula (I), stereoisomers thereof, or pharmaceutically acceptable salts of said compounds or stereoisomers wherein R1 and R2 are as defined herein as well as compositions comprising the same, processes for making the same, and methods of using the same to treat a variety of diseases, including, those requiring interaction with metalloproteases, and more specifically with macrophage metalloelastase (MMP-12), and for the prevention and treatment of respiratory pathologies such as chronic obstructive bronchopneumopathy (COPD), emphysema, chronic bronchitis, chronic pulmonary inflammation, asthma, cystic fibrosis, acute respiratory distress syndrome (ARDS), respiratory allergies including allergic rhinitis, and also diseases associated with the production of TNFα including severe fibrotic pulmonary disease, pulmonary sarcoidosis and silicosis. The compounds of the present invention also show inhibitory activity on metalloprotease-13 (MMP-13), making them useful for the treatment of pathologies involving this enzyme, such as cancer, osteoporosis, osteoarthritis, arthritis, rheumatoid arthritis, atherosclerosis, multiple sclerosis and cardiac insufficiency.

Pharmaceutical compositions consisting of diphenhydramine tannate which are effective when administered for the symptomatic relief of sneezing, itchy, watery eyes, itchy nose or throat and runny nose due to hay fever (allergic rhinitis) or other respiratory allergies are disclosed.

This invention pertains to inhibitors of atrial natriuretic peptide receptor A (NPRA) function, such as small interfering RNA (siRNA), useful for reducing the inflammation associated with many human diseases, such as asthma, respiratory syncytial virus (RSV) infection, and cancers (such as melanoma, lung cancer, and / or ovarian cancer) by interfering with NPRA gene expression or otherwise reducing NPRA function within a subject; and methods for treating a subject suffering from, or at risk of developing, an inflammatory disease, respiratory allergy (such as allergic rhinitis and asthma), viral infection, and / or cancer by administering such NPRA inhibitors to the subject.

The invention relates to the field of medical instruments, specifically to an allergen obstructing agent for the respiratory tract. The allergen obstructing agent comprises, by weight, 65 to 85% of white oil, 5 to 25% of Vaseline, 5 to 25% of paraffin and 5 to 25% of microcrystalline wax. A preparation method for the allergen obstructing agent comprises the following steps: mixing all the above-mentioned components; heating the obtained mixture to 60 to 120 DEG C and carrying out stirring at the same time; and carrying out cooling after full mixing so as to obtain the finished allergen obstructing agent. According to embodiments in the invention, the allergen obstructing agent can form a protection film with strong adhesion in the nasal cavity to obstruct immediate allergy induced by inhalation allergen and mitigates symptoms of inhalation allergy, thereby achieving a curative effect on prevention of immediate allergy.

A composition comprising specific Lactobacillus helveticus strains is provided for reducing the symptoms of allergies originating from food, respiratory or contact allergens. Preferably the composition reduces symptoms of allergies (secondary prevention)while also able to reduce sensitization (primary prevention).

A composition comprising specific Lactobacillus helveticus strains is provided for reducing the symptoms of allergies originating from food, respiratory or contact allergens. Preferably the composition reduces symptoms of allergies (secondary prevention) while also able to reduce sensitization (primary prevention).

A composition comprising specific Lactobacillus helveticus strains is provided for reducing the symptoms of allergies originating from food, respiratory or contact allergens. Preferably the composition reduces symptoms of allergies (secondary prevention) while also able to reduce sensitization (primary prevention).

The invention provides a chewable gel dosage form that contains at least one active agent and a method of administering such chewable gel dosage form to subjects to treat one or more indications associated with the active agent(s). In one embodiment, the invention provides a method for the temporary relief of symptoms to due hay fever and upper respiratory allergies comprising administering to a subject in need thereof a chewable gel dosage form comprising a therapeutically effective amount of loratadine and a gelling agent, wherein therapeutic efficacy is achieved under fasted or fed conditions.

The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children. The invention also relates to compositions for use in such methods, as well as their manufacture. The invention may be used to cause protection against any allergy, particularly food or respiratory allergies.

The invention belongs to the field of traditional Chinese medicine, and relates to a pharmaceutical composition containing traditional Chinese medicinal active components baicalin, icariin and astragaloside IV for preventing and treating respiratory anaphylactic disease. The invention determines the dose range of the traditional Chinese medicinal active components for inhibiting splenic lymphopoiesis of sensitized mice; and proven by further experiments in vitro, compared with single use of baicalin, icariin and astragaloside IV, the pharmaceutical composition provided by the invention has a stronger effect on inhibiting the splenic lymphopoiesis of sensitized mice, and a stronger effect on regulating Th cell differentiation and transformation of corresponding cell factors into the normalstate. The pharmaceutical composition provided by the invention can be used for further preparing a target organ protecting medicament, and preparing a monomer small compound medicament for improvingthe body immunity and preventing and treating respiratory anaphylactic disease.

The invention discloses an external-applied medicine capable of alleviating respiratory tract allergy. Ointment is prepared by grinding rhizoma coptidis, asarum, frankincense, borneol and wild aconite roots into powder, and mixing the power with monoglyceride. The ointment has a powerful anaesthetization osmosis effect, and can effectively alleviate discomfort symptoms caused by allergy.

The invention refers to pharmaceutical compositions based on oil extracted from the seeds of Carapa Guianensis Aublet and / or of chemical compounds isolated from this oil and responsible for its biological activity, the tetranortriterpenoids, presenting the following pharmacological activities: anti-allergenic, anti-inflammatory, analgesic and immune modulating with reduced side effects and low cost. Such pharmaceutical compositions of this invention are aimed at the treatment, or prevention, or inhibition of allergenic an inflammatory conditions in human beings, through oral or topic use. In each one of these cases, the composition can be in the liquid or solid form. Compounds for topic use of this invention are atoxic, or with low toxicity, and, specially, provided in the semi-solid form (cream). The pharmaceutical compositions of this invention constitute an important therapeutic alternative for cutaneous and respiratory allergies, besides acting in different inflammatory reactions of allergenic origin or infectious origin. Therefore, these compositions are also used in the symptomatic treatment of rheumatic, inflammatory and degenerative processes, diverse traumas, pain and post surgery inflammation, acute painful syndromes, among others and it can be orally or topically administered.

A method relates to epigenetic markers and their diagnostic and predictive value for respiratory allergy. The method can include assaying a test sample from the patient for a DNA hypermethylation or hypomethylation of at least GLI2 region, in which hypermethylation or hypomethylation of the gene region in the test sample indicates or predicts a respiratory allergy in the patient.

The invention discloses a composite pellet soil additive and a composite pellet soil production method. The composite pellet soil additive comprises a formula A and a formula B. The formula A is prepared from 1 part of lauryl sodium sulfate, 1 part of sodium polyacrylate, 1 part of polyacrylamide and 3 parts of high-viscosity CMC. The formula B is prepared from 1 part of the lauryl sodium sulfate, 1 part of the sodium polyacrylate, 1 part of the polyacrylamide and 3 parts of polyvinyl alcohol. According to the composite pellet soil additive and the composite pellet soil production method, a prepared product is based on the principles of good biodegradability and low toxicity, the lauryl sodium sulfate is used as an emulsifier of medicines and cosmetics, a foaming agent of toothpaste, a fire extinguisher and a raw material of a detergent, and irritates respiratory tracts to cause respiratory tract allergy, and when the product is used, a user wears a dustproof mask, and the other components are non-toxic.

The invention discloses a compound pigeon manure traditional Chinese medicinal composition for treating allergic diseases, a preparation method and application. The traditional Chinese medicinal composition comprises 10 parts of pigeon manure, 0 to 1 part of impatiens balsamina, and an auxiliary including 0 to 1.5 parts of albizia julibrissin durazz. or 0 to 1 part of nostoc commune; or 10 parts of pigeon manure, 0.8 to 1 part of impatiens balsamina and 1.2 to 1.5 parts of albizia julibrissin durazz.; or 10 parts of pigeon manure, 0.8 to 1 part of impatiens balsamina and 0.1 to 1 part of nostoc commune; or 10 parts of pigeon manure, 0.8 to 1 part of impatiens balsamina, 1.2 to 1.5 parts of albizia julibrissin durazz. and 0.1 to 1 part of nostoc commune. Except the impatiens balsamina, each of the other medicinal materials is independently fried, and then each fried traditional Chinese herbal medicinal material is proportionally mixed and crushed with the impatiens balsamina to finally obtain fine powder; an oral powder or liquid finished product is prepared; or oral capsules are prepared; or a powdery product for a patient to inhale is prepared. The traditional Chinese medicinal composition is mainly used for treating respiratory allergies, comprising bronchial asthma, cough variant asthma and allergic rhinitis, or treating allergic skin diseases, comprising urticaria, anaphylactoid purpura and cutis indurativa tuberculosis. The diseases can be radically treated.

The present invention discloses the detection of an important 12K-Da protein having cross-reactivity amongst different prevalent allergenic grasses and fungi can be useful for detection of respiratory allergies. Conventionally, the whole extracts that are used for diagnosis are unable to specifically detect the causative agents. In addition, they are also responsible for additional non-specific sensitivities in patients to other components present in the extract. If a single cross-reactive protein is available, it can replace large number of extracts used for detection of raised IgE levels in allergy by ELISA, immunoblotting and the likes. Further, number of pricks would be reduced and this would benefit both patient and clinicians. It is further realized that production of such a protein by recombinant methods can lead to its availability in pure form and bulk amounts required for routine diagnosis.

The present invention provides a recombinant protein or a derivative thereof, wherein the recombinant protein has an amino acid sequence of the N-terminal portion of CC chemokine receptor 4 (CCR4). The invention also provides the use of the recombinant protein or a derivative thereof for treating or preventing a disease or condition associated with CCR4 signaling, such as an allergic disease, inflammatory enteritis, psoriasis, an inflammatory skin disease, vasculitis, spondyloarthropathy, scleroderma, asthma, a respiratory allergic disease, an autoimmune disease, graft rejection, leukemia, lymphoma, a blood-borne cancer, a disease requiring inhibition of undesirable inflammation, and a cancer.

The present invention discloses the detection of an important 12K-Da protein having cross-reactivity amongst different prevalent allergenic grasses and fungi can be useful for detection of respiratory allergies. Conventionally, the whole extracts that are used for diagnosis are unable to specifically detect the causative agents. In addition, they are also responsible for additional non-specific sensitivities in patients to other components present in the extract. If a single cross-reactive protein is available, it can replace large number of extracts used for detection of raised IgE levels in allergy by ELISA, immunoblotting and the likes. Further, number of pricks would be reduced and this would benefit both patient and clinicians. It is further realized that production of such a protein by recombinant methods can lead to its availability in pure form and bulk amounts required for routine diagnosis.

The invention belongs to the field of traditional Chinese medicine, and relates to a pharmaceutical composition containing traditional Chinese medicinal active components baicalin, icariin and astragaloside IV for preventing and treating respiratory anaphylactic disease. The invention determines the dose range of the traditional Chinese medicinal active components for inhibiting splenic lymphopoiesis of sensitized mice; and proven by further experiments in vitro, compared with single use of baicalin, icariin and astragaloside IV, the pharmaceutical composition provided by the invention has a stronger effect on inhibiting the splenic lymphopoiesis of sensitized mice, and a stronger effect on regulating Th cell differentiation and transformation of corresponding cell factors into the normalstate. The pharmaceutical composition provided by the invention can be used for further preparing a target organ protecting medicament, and preparing a monomer small compound medicament for improvingthe body immunity and preventing and treating respiratory anaphylactic disease.

The invention discloses a double-layer horseradish buccal tablet for resisting respiratory tract allergy and belongs to the technical field of health foods or functional foods. The double-layer horseradish buccal tablet is composed of contents and a soluble shell for covering the contents; the contents are horseradish powder or horseradish powder and auxiliary materials required by a preparation process; the shell contains tamarind powder and menthol as well as the auxiliary materials required by the preparation process. The tamarind powder and the menthol have the effect of promoting salivary secretion; water in saliva provides a condition for an enzymatic reaction of the horseradish powder and involves in action of sinigrin and sinigrin enzyme; by the effects of the saliva of the oral cavity and the enzyme, the horseradish powder passes through plant cell walls and releases allyl isothiocyanate within a short time. Due to the temperature of 36 to 37 DEG C in the oral cavity, the enzymatic reaction process and the release of the allyl isothiocyanate are quickened, and the allyl isothiocyanate gets a relatively high concentration in the oral cavity within a short time, so that the allergy can be relieved in an acute stage of the respiratory tract allergy. The double-layer horseradish buccal tablet has a definite effect on the respiratory tract allergy and is goo in taste, low in production cost, convenient to carry and long in quality guarantee period.

The invention discloses a traditional Chinese medicine mask for treating lung heat type acne. The traditional Chinese medicine mask is prepared from rhubarb, white mulberry root bark, loquat leaf, dahurian angelica root, fructus forsythiae, red sage root, Chinese angelica, dandelion and borneol, and has the effects of clearing away heat and toxic materials, promoting blood circulation to remove blood stasis, diminishing swelling and removing stasis. No allergy discomfort or skin intolerance to various components is found in the use process, no respiratory tract allergy symptom of a patient to a certain component in the mask is found at present, and light and medium acne, rosacea, hormone-dependent dermatitis furuncle and contact dermatitis accompanied by inflammation are well improved.